Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Ellipta inhaler products
With over 40 ways to construct a triple therapy in 2019, we recognise the complexity that you face in your practice. That is why we have developed a portfolio of evidence-based medicines, all delivered in the same easy-to-use device, which has been designed specifically to suit the inspiratory flow rates of your patient.
To find out how the Ellipta portfolio can help your patients, explore the products below:
Trelegy▼ Ellipta (fluticasone furoate / umeclidinium / vilanterol)
COPD
Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA). 1
Anoro▼ Ellipta (umeclidinium / vilanterol inhalation powder)
COPD
Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 2
Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)
Asthma
Relvar Ellipta (92 micrograms/22 micrograms inhalation powder and 184 micrograms/22 micrograms inhalation powder) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists; patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist. 3 4
Incruse▼ Ellipta (umeclidinium bromide inhalation powder)
COPD
Incruse Ellipta is indicated for the ‘maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Other products in our Respiratory portfolio
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Anoro, Incruse, Relvar, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies
